Tryptamine Therapeutics Ltd. is gearing up to enter the clinic with lead compound TRP-8803, an intravenous-infused psilocybin therapy, in patients with binge eating disorder in conjunction with ...

The open-label trial will be run in partnership with Swinburne University and plans to test Tryptamine’s IV psilocin therapy TRP-8803, with supportive psychotherapy. Watch the video to hear the ...

Tryptamine Therapeutics (AU:TYP) has released an update. Tryptamine Therapeutics Limited, now trading on the ASX under the ticker TYP, has raised $6.5 million to advance its clinical trials, including ...

Tryptamine Therapeutics has entered an exclusive agreement with world-leading psychedelic researchers to develop a first-of-its-kind EEG-based brain entropy biomarker. Carhart-Harris, who is chair of ...

Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter ...